Alpha 1-antitrypsin deficiency laboratory tests

Revision as of 15:26, 1 June 2016 by Anthony Gallo (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Alpha 1-antitrypsin deficiency Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Alpha 1-antitrypsin deficiency from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications, and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Alpha 1-antitrypsin deficiency laboratory tests On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Alpha 1-antitrypsin deficiency laboratory tests

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Alpha 1-antitrypsin deficiency laboratory tests

CDC on Alpha 1-antitrypsin deficiency laboratory tests

Alpha 1-antitrypsin deficiency laboratory tests in the news

Blogs on Alpha 1-antitrypsin deficiency laboratory tests

Directions to Hospitals Treating Alpha 1-antitrypsin deficiency

Risk calculators and risk factors for Alpha 1-antitrypsin deficiency laboratory tests

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:

Overview

Laboratory Findings

The diagnosis of alpha-1 AT deficiency should be suspected in any patient who:

  1. Develops emphysema younger than 45 years old, if they are a non/minimal smoker, or if they have primarily basilar disease OR
  2. Has a history of panniculitis or
  3. Has or has a family history of unexplained liver disease (especially cirrhosis or hepatoma).
  • In suspected individuals the initial step is to measure the serum alpha-1 AT concentration.
  • In general, phenotyping should be reserved for patients who have low or borderline low alpha-1 AT levels.
  • PFTs-pulmonary function tests (spirometry pre and post bronchodilators, lung volumes and diffusing capacity),
  • LFTs (liver function test)
  • ABG-arterial blood gases (usually)

References


Template:WikiDoc Sources